Nature Reviews Clinical Oncology 6, 371 (2009). doi:10.1038/nrclinonc.2009.93

Author: Vincent T. DeVita

I am often asked my opinion of the most important presentation at the annual ASCO meetings. I gave up long ago trying to explain that it is impossible to read the thousands of abstracts and rate them accordingly, but like everyone else I do keep

Nature Reviews Clinical Oncology 6, 373 (2009). doi:10.1038/nrclinonc.2009.75

Author: Mandy Aujla

TP53

Nature Reviews Clinical Oncology 6, 379 (2009). doi:10.1038/nrclinonc.2009.83

Authors: Sharlene Gill & Richard M. Goldberg

The first-line treatment for patients with unresectable metastatic colorectal cancer is chemotherapy in combination with bevacizumab. Emerging evidence, however, suggests that the addition of cetuximab—an anti-EGFR monoclonal antibody—to chemotherapy might be beneficial to patients with wild-type KRAS tumors.

Nature Reviews Clinical Oncology 6, 380 (2009). doi:10.1038/nrclinonc.2009.87

Authors: Jennifer R. Brown & Arnold S. Freedman

The use of autologous stem-cell transplantation in the treatment of follicular lymphoma remains controversial. Results from the GOELAMS trial show a higher progression-free survival rate in patients treated with autologous stem-cell transplantation compared to those treated with chemotherapy.

Nature Reviews Clinical Oncology 6, 382 (2009). doi:10.1038/nrclinonc.2009.88

Authors: Kimberly E. Resnick, David E. Cohn & Jeffrey M. Fowler

Pelvic lymphadenectomy offers no therapeutic benefit to women diagnosed with early-stage endometrial cancer according to a new study. Lymphadenectomy can only be recommended as part of a clinical trial in this disease setting; however, it can offer valuable staging information in those with advanced disease.

Nature Reviews Clinical Oncology 6, 384 (2009). doi:10.1038/nrclinonc.2009.85

Author: Anthony B. Miller

A study of cervical cancer screening in 52 villages in India has shown that a single round of human papillomavirus testing was linked to a significant reduction in the number of deaths from cervical cancer, compared with other screening methods. This has implications for primary screening in low-resource settings.

Nature Reviews Clinical Oncology 6, 385 (2009). doi:10.1038/nrclinonc.2009.86

Authors: Martin Weiser & Leonard Saltz

The role of laparoscopic resection for rectal cancer is currently unclear, with little supportive evidence from randomized trials. A study by Ng et al. in a large series of patients with rectal cancer has shown that laparoscopic resection is safe with good long-term outcomes.

Nature Reviews Clinical Oncology 6, 387 (2009). doi:10.1038/nrclinonc.2009.73

Authors: Hideko Yamauchi, Massimo Cristofanilli, Seigo Nakamura, Gabriel N. Hortobagyi & Naoto T. Ueno

Despite progress in combined-modality treatment with chemotherapy, surgery, and radiation therapy, the long-term outcome for patients with inflammatory breast cancer (IBC) remains poor. Therapies that target vasculolymphatic processes—angiogenesis, lymphangiogenesis, and vasculogenesis—have shown potential in the treatment for IBC, as represented by bevacizumab. Although the therapeutic

Nature Reviews Clinical Oncology 6, 395 (2009). doi:10.1038/nrclinonc.2009.52

Authors: Victoria L. Heath & Roy Bicknell

The growth and metastasis of solid tumors critically depends on their ability to develop their own blood supply, a process known as tumor angiogenesis. Over the past decade much work has been performed to understand this process, and modifying this process provides a key point

Nature Reviews Clinical Oncology 6, 405 (2009). doi:10.1038/nrclinonc.2009.72

Authors: Lisa Pleyer, Alexander Egle, Tanja Nicole Hartmann & Richard Greil

The mainstay of therapy of chronic lymphocytic leukemia (CLL) is cytotoxic chemotherapy; however, CLL is still an incurable disease with resistance to therapy developing in the majority of patients. In recent years, our understanding of the biological basis of CLL pathogenesis has substantially improved and

Nature Reviews Clinical Oncology 6, 419 (2009). doi:10.1038/nrclinonc.2009.82

Authors: Volker Fendrich, Jens Waldmann, Detlef K. Bartsch & Peter Langer

Pancreatic endocrine tumors (PETs) are uncommon but clinically challenging and fascinating tumors with an annual incidence of 1 per 100,000 people. PETs present as either functional pancreatic tumors or as nonfunctional pancreatic tumors. Functional tumors are commonly associated with a specific hormonal syndrome directly related

Nature Reviews Clinical Oncology 6, 429 (2009). doi:10.1038/nrclinonc.2009.70

Authors: Sanjeev Bhattacharyya, Dorothy M. Gujral, Christos Toumpanakis, Gilles Dreyfus, Brian R. Davidson, Joseph Davar & Martyn E. Caplin

Background. A 48-year-old man presented with diarrhea, flushing, abdominal pain and weight loss of 10 kg over a 6-month period. He subsequently developed dyspnea on exertion.Investigations. Physical examination, laboratory tests, CT of the abdomen, liver biopsy, echocardiography, immunohistochemistry staining of the biopsy